Ampio Pharmaceuticals stock analysis
Want to see AMPE full AI Analyst Report?
Ampio Pharmaceuticals (AMPE) Stock Price & Analysis
AMPE Stock Chart & Stats
- Day’s Range
- $0.18 - $0.18
- 52-Week Range
- $0.01 - $0.64
- Previous Close
- $0.18
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $207.88K
- Enterprise Value
- -$3.61T
- Total Cash (Recent Filing)
- $4.09M
- Total Debt (Recent Filing)
- $274.00K
- Price to Earnings (P/E)
- ―
- Beta
- 42.76
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Low leverage indicates that the company has not overburdened itself with debt, which can be advantageous in maintaining financial flexibility and reducing risk during periods of financial distress.
Asset Stability
Maintaining a positive equity ratio suggests that despite financial challenges, the company has managed to keep its assets stable, which is crucial for long-term operational sustainability.
Innovative Treatment Approach
Focusing on innovative treatments for prevalent conditions like osteoarthritis positions Ampio to potentially capture significant market share if successful, providing a strong foundation for future growth.
Bears Say
Zero Revenue
The lack of revenue generation over an extended period highlights significant challenges in commercializing products, which is critical for sustaining operations and achieving profitability.
Negative Cash Flow
Persistent negative cash flow indicates the company struggles to generate sufficient cash from its operations, posing risks to its ability to finance ongoing activities and future growth.
Ongoing Losses
Continued operating losses suggest difficulties in achieving profitability, which can hinder the company's ability to invest in research, development, and expansion efforts.
Ampio Pharmaceuticals News
Ampio reports results from OA-201 studies do not support IND submission
Ampio announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio’s only product development opportunity. Ampio reported that the efficacy results of these studies do not
AMPE FAQ
What was Ampio Pharmaceuticals’s price range in the past 12 months?
What is Ampio Pharmaceuticals’s market cap?
When is Ampio Pharmaceuticals’s upcoming earnings report date?
How were Ampio Pharmaceuticals’s earnings last quarter?
Is Ampio Pharmaceuticals overvalued?
Does Ampio Pharmaceuticals pay dividends?
What is Ampio Pharmaceuticals’s EPS estimate?
How many shares outstanding does Ampio Pharmaceuticals have?
What happened to Ampio Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ampio Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc., headquartered in Englewood, Colorado, is a biopharmaceutical firm dedicated to advancing immunomodulatory therapeutics primarily for the management of osteoarthritis pain across the United States. Their developmental pipeline currently features several compounds: AP-013, an intra-articular injection, is undergoing Phase III clinical trials for knee osteoarthritis. Additionally, the company has multiple candidates addressing COVID-19: AP-017, an intravenous Ampion formulation, is in Phase II for adult COVID-19 patients who require supplemental oxygen; AP-019, an inhaled Ampion treatment, also in Phase II, targets adults experiencing respiratory distress from COVID-19; while AP-018, currently in Phase I, aims to treat individuals with persistent respiratory symptoms following COVID-19 infection.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael A. Martino
- Employees
- 6
- Website
- www.ampiopharma.com
- Address
- 9800 Mount Pyramid Court, Englewood, CO, 80112, US
Ampio Pharmaceuticals (AMPE) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 1 | 11 |
| Technical Analysis | 5 | 1 | 2 |
| Moving Averages | 3 | 0 | 9 |










